Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OMTRYG vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OMTRYG is a combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that blocks viral RNA replication and assembly. Paritaprevir is an NS3/4A protease inhibitor that prevents viral polyprotein cleavage. Ritonavir is a CYP3A4 inhibitor used to boost paritaprevir levels.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Treatment of chronic hepatitis C virus (HCV) genotype 4 infection without cirrhosis or with compensated cirrhosis,Treatment of chronic HCV genotype 1 infection (with ribavirin or as part of combination therapy)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
2 mg orally twice daily; if taste disturbance occurs, reduce to 1 mg twice daily.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is 12-14 hours in healthy adults, allowing once-daily dosing. In renal impairment (Cr Cl <30 m L/min), half-life prolongs to 24-36 hours requiring dose adjustment.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Ombitasvir: primarily metabolized by CYP3A4; Paritaprevir: primarily metabolized by CYP3A4; Ritonavir: primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily renal excretion unchanged (approximately 70%), with 30% metabolized hepatically and excreted in feces via bile. Renal clearance accounts for ~60% of total clearance.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 95% bound to serum albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and plasma with limited tissue penetration.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 60-80% (first-pass effect); Subcutaneous: 90-100%.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
No dose adjustment required for GFR ≥30 m L/min; avoid use if GFR <30 m L/min.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No dose adjustment required for Child-Pugh A or B; not recommended in Child-Pugh C due to lack of data.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
No dose adjustment required based on age; monitor for taste disturbance and renal function.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
WARNING: HEPATITIS B VIRUS REACTIVATION — Test all patients for evidence of current or prior HBV infection before initiating treatment. HBV reactivation has been reported in patients coinfected with HCV and HBV, which can result in fulminant hepatitis, hepatic failure, and death.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Risk of hepatitis B virus reactivation,Hepatic decompensation/hepatic failure in patients with cirrhosis,ALT elevations and hepatic injury,Risk of drug interactions (significant CYP3A4 inhibition),Use with ribavirin: ribavirin-related adverse effects (e.g., anemia, teratogenicity)
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Severe hepatic impairment (Child-Pugh C),Known hypersensitivity to ombitasvir, paritaprevir, ritonavir, or any component of the formulation,Coadministration with drugs highly dependent on CYP3A4 for clearance (e.g., alfuzosin, amiodarone, sildenafil when used for pulmonary arterial hypertension, ergot derivatives, lovastatin, simvastatin, midazolam, triazolam),Moderate to severe hepatic impairment in patients with cirrhosis (Child-Pugh B and C)
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No clinically significant food interactions reported.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Pregnancy Category X: contraindicated in pregnancy. First trimester: major congenital malformations (e.g., neural tube defects, cardiac anomalies). Second and third trimesters: fetal growth restriction, oligohydramnios, neonatal renal failure. Risk is dose-dependent.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Contraindicated during breastfeeding. M/P ratio not established; drug excreted into breast milk. Potential for serious adverse effects in nursing infant (renal toxicity).
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Not applicable; contraindicated in pregnancy. No dose adjustment recommended due to contraindication.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
OMTRYG (triptorelin pamoate) is a Gn RH agonist used for advanced prostate cancer. Monitor for tumor flare at therapy initiation; consider antiandrogen coadministration for first month. Baseline and periodic serum testosterone and PSA levels are essential. Caution in patients with spinal cord compression or urinary tract obstruction. Risk of QT prolongation; assess electrolytes and ECG in at-risk patients. Depot formulation provides 6-month coverage.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
OMTRYG is injected every 6 months by a healthcare provider.,You may experience a temporary increase in bone pain or urinary symptoms during the first few weeks.,Report new or worsening pain, difficulty urinating, or leg weakness immediately.,Hot flashes, decreased libido, and erectile dysfunction are common.,Do not stop treatment without consulting your doctor.,Keep all scheduled injections; missed doses can reduce effectiveness.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OMTRYG vs ACTIQ, answered by our medical review team.
OMTRYG is a HMG-CoA Reductase Inhibitor (Statin) that works by OMTRYG is a combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that blocks viral RNA replication and assembly. Paritaprevir is an NS3/4A protease inhibitor that prevents viral polyprotein cleavage. Ritonavir is a CYP3A4 inhibitor used to boost paritaprevir levels.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OMTRYG and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OMTRYG is: 2 mg orally twice daily; if taste disturbance occurs, reduce to 1 mg twice daily.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OMTRYG and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OMTRYG is classified as Category C. Pregnancy Category X: contraindicated in pregnancy. First trimester: major congenital malformations (e.g., neural tube defects, cardiac anomalies). Second and third trimesters: fet. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.